Amplimmune
Date | Investors | Amount | Round |
---|---|---|---|
$20.0m | Series A | ||
$500m Valuation: $500m | Acquisition | ||
Total Funding | AUD30.9m |
Recent News about Amplimmune
EditAmplimmune is a biotechnology company focused on developing innovative immunotherapy solutions to treat cancer and autoimmune diseases. The company operates in the biopharmaceutical market, targeting healthcare providers and patients who require advanced therapeutic options. Amplimmune's business model revolves around research and development, leveraging cutting-edge science to create novel treatments that modulate the immune system. Revenue is generated through partnerships, licensing agreements, and the commercialization of its proprietary therapies. The company aims to push the boundaries of science to deliver life-changing medicines, ensuring high-quality medical and scientific information exchange. Amplimmune's commitment to innovation and patient care positions it as a key player in the biopharmaceutical industry.
Keywords: immunotherapy, cancer, autoimmune diseases, biotechnology, biopharmaceutical, healthcare, innovation, research, development, therapies.